ArticleClinical, cosmetic and investigational dermatology2026
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Five-Year Experience at a Tertiary Referral Hospital in Somalia.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To describe the clinical characteristics, suspected drug triggers, management, and in-hospital outcomes of patients with Stevens-Johnson syndrome (SJS), SJS/toxic epidermal necrolysis (TEN) overlap, or TEN at a tertiary referral hospital in Somalia. Patients and Methods: This retrospective descriptive study included 37 patients admitted from January 2020 through December 2025. Age was categorized as 1-18, 19-49, and ≥50 years. Final clinician-documented diagnoses, demographic and clinical characteristics, suspected drugs, first-admission laboratory classifications, documented treatments, intensive care unit (ICU) admission, complications, length of stay, and survival were summarized using counts and percentages. Standardized SCORTEN and ALDEN assessments were unavailable. Mortality modeling was not performed because only seven deaths occurred and the extracted data were insufficient for a stable multivariable model. Results: Of 37 patients, five (13.5%) were aged 1-18 years, 18 (48.6%) were aged 19-49 years, and 14 (37.8%) were aged ≥50 years; 23 (62.2%) were female. Final clinician-documented diagnoses were TEN in 27 (73.0%), SJS/TEN overlap in six (16.2%), and SJS in four (10.8%). Antibacterial agents accounted for 26 (70.3%) suspected exposures, including other beta-lactams, trimethoprim-sulfamethoxazole, ceftriaxone, and amikacin. Laboratory findings indicated significant systemic involvement, including elevated inflammatory markers and liver enzymes. Prednisolone was widely used (94.6%), and more than half of patients received cyclosporine (56.8%), while IVIG use was minimal (2.7%). Nine patients (24.3%) required ICU admission. The overall in-hospital mortality rate was 18.9% (7/37). Conclusion: This single-center cohort was characterized by frequent suspected antibacterial drug exposure, a high proportion of clinician-documented TEN, and substantial in-hospital mortality. Because the study was small and retrospective and lacked standardized severity and drug-causality assessments, it cannot establish treatment effects or mortality predictors. Prospective multicenter studies using SCORTEN, ALDEN, standardized treatment documentation, and long-term follow-up are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.